Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Currently 0/5 right?
I'm still here because of penny and 100million. Thanks guys.
Copy and paste the article.
Good stuff this morning boyz.
It's actually pretty pathetic at this point.
I was just asking why there was no PR on previously unreleased data good enough to publish in a scientific journal that is presented at a major conference. Bizarre.
No kidding but I went to option 2 when option one wouldn't work. Now neither does. :)
Even voicemail?
I did that already. I must be on the sh$t list.
So I've sent roughly 5-6 emails and a couple of voicemails to IR over the course of the last couple of months and I've never gotten a response. Kind of lame
That would be a great guess
Ok, I had to look some of the codes up. So:
Chicago, Milwaukee, New York, Minneapolis, Dallas, Denver, New York, Boston. All investor meetings. Love it. Good DD would be to find the hedge funds in each city.
It is being presented there in some shape or form because the section of the journal where it is located is in the section titled abstracts for the meeting. Either way, good stuff. My guess is that Daud will explain the details. Very similar to last year where Daud was speaking at a sitc regional meeting with talk title that was generic but that is where they presented the interim melanoma data in December 16, 2013.
Actually, I really hope I lose.
I'll make you a deal: if you find anything substantive about oncs before anyone else (not including posts already on yahoo), I will never criticize your posting again. Simple enough. Now the whole board is watching: GO!
At the pps celebration party in Las Vegas. :)
Guess what I found. Pretty sure we are going to get a good PR Monday. ONCS is presenting at Melanoma Congress in Zurich (November 13-16) and have a published abstract already published in the "Pigment Cell & Melanoma Research" Journal. Heller is the lead author. Yes, I am a Ninja!!!!
http://onlinelibrary.wiley.com/doi/10.1111/pcmr.12317/full
"Delivery of plasmid encoding IL-12 by electrotransfer for effective immunotherapy
R. Heller1, R. Pierce2, T. Takamura2, C. Lundberg1, N. Burcus1, T. Diep2, A. Daud3, S. Shirley1
1Old Dominion University, Norfolk, VA, USA2OncoSec Medical Corp, San Diego, CA, USA3University of California San Francisco, San Francisco, CA, USA
Gene electrotransfer (GET) of a plasmid encoding interleukin-12 (pIL-12) to tumors has been shown to generate a local and systemic anti-tumor effect in both preclinical and clinical studies. Interestingly, the delivery parameters directly influence the nature of the immune response against melanoma tumors. To obtain the appropriate immune stimulation it is critical to achieve the appropriate balance between transgene expression and tissue damage. In this study, we have evaluated various electrotransfer parameters and how the expression patterns effected long-term disease free survival. Plasmid DNA was injected into established B16.F10 melanoma tumors of C57BL/6 mice and electric pulses applied three times over a 1 week period. While a response was seen in all tumors treated with GET pIL-12 irrespective of parameters used, disease free long-term survival and protection following subsequent challenge was directly related to expression levels and kinetics of the delivered transgene. Mice resistant to challenge were found to have a higher level of memory T-cells and effector cells. Although delivery with GET parameters of 1300 V/cm 100 microsecond pulse width resulted in moderate to low expression levels, these conditions induced the highest level of protection. These results indicate the appropriate levels of cytokine expression in tumors delivered by electrotransfer necessary for generating local and systemic anti-tumor response that correspond with a more successful outcome. Additional studies have evaluated response and immune stimulation in a multi tumor mouse model. Evaluation of potentially combining this approach with other therapies to enhance the distant response is ongoing. The results from these preclinical studies combined with results from clinical studies utilizing GET of pIL-12 have the potential to improve electrotransfer-based therapies for melanoma patients"
I think there is going to be a lot of covering today from the last two days before the weekend.
No!!!! Don't do it Penney. Don't pull out the 0/5 milestone card today. Please. And please don't Twitter Punit about the milestones. Let's find this MCC together. You will then be a ninja.
Baby steps sal. He did something helpful. Encourage this.
I know you do. Now you are putting your "caring" energy into DD which is extremely helpful to me and the rest of the board instead of whining which isn't helpful to anyone. That was actually a great find. Now, join me in trying to find MCC data. Be a ninja Penney!!!:)
Good DD Penney!!!
Go to their website. Do you have a computer?
Ya. They have 3 consecutive weeks of conferences that are made to connect institutional investors to senior management. Today, 19th, 24th.
ONCS' message to institutional investors: Get in before its too late. This is the theme of November. All their events are targeted at institutional investors and they publicly put out the melanoma bridge early to show them that the fun is beginning soon.
From Stifel:
"Our conferences are designed to connect the dots and provide original perspective and depth of insight that are rare at most investor conferences. The goal of each conference is to provide institutional investors with high-level access to senior management and industry experts, showcase dynamic emerging companies and investigate critical trends that are driving our economy."
http://www.tweisel.com/Stifel/ConferencesAndEvents/Calendar/
Holding up pretty well. Time to take out .58!
Well, when buyers go through 300,000 shares in 20 sec, it appears effortless. :)
Oh boy!
If you all want to see a good comparison to us: NVIV. Driven down to .46 on 9/10/2014. Today 1.39 and rising.
Almost to .55.
Good, consistent buying today. Should retest .55 (hopefully).
You didn't really answer my question but who cares because I agree.
Swaltz4: what did think of my differentiating attempt and the type of run we are going to have. Think I've full of crap or on to something?
The upcoming run!!!
Know you don't.
Certainly getting interesting.
Very telling isn't it! Hmmm